Results 21 to 30 of about 36,094 (222)
Aggressive prostate cancer is associated with pericyte dysfunction
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero +11 more
wiley +1 more source
Evaluación de la calidad de vida de pacientes oncológicos en tratamiento quimioterápico complementar [PDF]
Estudo do tipo exploratório descritivo que objetivou avaliar a qualidade de vida de pacientes com câncer de mama e intestino, no início e três meses após o tratamento quimioterápico.
MACHADO, Sheila Mara +1 more
core +2 more sources
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He +8 more
wiley +1 more source
Strength through diversity: how cancers thrive when clones cooperate
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken +3 more
wiley +1 more source
Polymorphism in genes of the progesterone receptor (PROGINS) in women with breast cancer: a case-control study [PDF]
PURPOSE: to analyze the correlation between PROGINS polymorphism and breast cancer. METHODS: a case-control study was carried out from April to October 2004. The genotypes of 50 women with breast cancer and 49 healthy women were analyzed.
Baracat, Fausto Farah +5 more
core +2 more sources
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source
Dinámica familiar: percepción de familias de sobrevivientes de cancer de mama [PDF]
O estudo teve como objetivo identificar as percepções de familiares sobre a dinâmica de suas famílias após o câncer de mama em um dos seus membros. Estudo de abordagem qualitativa que tomou como referencial teórico o modelo de funcionamento familiar ...
BIFFI, Raquel Gabrielli +1 more
core +3 more sources
Targeting p38α in cancer: challenges, opportunities, and emerging strategies
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley +1 more source
Análise da comunicação médico-paciente em caso de diagnóstico de câncer de mama [PDF]
The aim of the paper is the recognition and evaluation of demand for medical information among patients suffering from breast cancer. The research was conducted among 120 women with diagnosed breast cancer in the Oncological Surgery Clinic of the ...
Goniewicz, Mariusz +4 more
core +2 more sources

